| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on June 1, 2004
Accepted on June 24, 2004
Institute of Genetics and Biophysics "Adriano Buzzati-Traverso", CNR, Naples, Italy, Department of General Surgery, Medical University of Gdansk, Poland, and the Departments of Medicine , Pediatrics and Surgery , Columbia University Medical School, New York, New York
* To whom correspondence should be addressed. E-mail: peh1{at}columbia.edu.
The purpose of our study was to identify transcripts specific for tissue-restricted membrane associated proteins in human islets that, in turn, might serve as markers of healthy or diseased islet cell masses. Using oligonucleotide chips, we obtained gene expression profiles of human islets for comparison to the profiles of exocrine pancreas, liver and kidney tissue. As peri-islet presence of type 1 interferon is associated with the development of type 1 diabetes, the expression profile of human islets treated ex vivo with interferon 
2
(IFN2) was also acquired. A set of genes encoding transmembrane or membrane-associated proteins with novel islet restricted expression was resolved by determining the intersection of the islet set with the complement of data sets obtained from other tissues. Under the influence of IFN 2, the expression levels of transcripts for several of the identified gene products were up or down regulated. One of the islet restricted gene products identified in this study, VMAT2, was shown to bind [3H] - dihydrotetrabenazine, a ligand with derivatives suitable for P.E.T. imaging. We report here the first comparison of gene expression profiles of human islets with other tissues and the identification of a target molecule with possible use in determining islet cell masses.
- Cells •
Islets •
Imaging •
T1D •
SSH
This article has been cited by other articles:
 |
|
 |
|
  A. T. Suckow, D. Comoletti, M. A. Waldrop, M. Mosedale, S. Egodage, P. Taylor, and S. D. Chessler Expression of Neurexin, Neuroligin, and Their Cytoplasmic Binding Partners in the Pancreatic {beta}-Cells and the Involvement of Neuroligin in Insulin Secretion Endocrinology, December 1, 2008; 149(12): 6006 - 6017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Raffo, K. Hancock, T. Polito, Y. Xie, G. Andan, P. Witkowski, M. Hardy, P. Barba, C. Ferrara, A. Maffei, et al. Role of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazine J. Endocrinol., July 1, 2008; 198(1): 41 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-P. Kung, C. Hou, B. P. Lieberman, S. Oya, D. E. Ponde, E. Blankemeyer, D. Skovronsky, M. R. Kilbourn, and H. F. Kung In Vivo Imaging of {beta}-Cell Mass in Rats Using 18F-FP-(+)-DTBZ: A Potential PET Ligand for Studying Diabetes Mellitus J. Nucl. Med., July 1, 2008; 49(7): 1171 - 1176. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
